Mouse IL-7 ELISA kit (4X96T)
- Known as:
- Mouse Interleukin-7 Enzyme-linked immunosorbent assay test reagent (4X96T)
- Catalog number:
- LF-EK50656
- Product Quantity:
- 4
- Category:
- Elisa Kits
- Supplier:
- Abfron
- Gene target:
- Mouse IL-7 ELISA kit (4X96T)
Related genes to: Mouse IL-7 ELISA kit (4X96T)
- Gene:
- IL7 NIH gene
- Name:
- interleukin 7
- Previous symbol:
- -
- Synonyms:
- IL-7
- Chromosome:
- 8q21.13
- Locus Type:
- gene with protein product
- Date approved:
- 1989-10-12
- Date modifiied:
- 2016-10-11
- Gene:
- IL7R NIH gene
- Name:
- interleukin 7 receptor
- Previous symbol:
- -
- Synonyms:
- CD127, IL7RA
- Chromosome:
- 5p13.2
- Locus Type:
- gene with protein product
- Date approved:
- 1991-08-07
- Date modifiied:
- 2019-04-23
Related products to: Mouse IL-7 ELISA kit (4X96T)
Related articles to: Mouse IL-7 ELISA kit (4X96T)
- Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease characterized by painful, inflamed lesions in the apocrine gland-bearing regions and systemic involvement. While inflammatory cytokines including IL-6 and IL-17A have been implicated in HS pathogenesis, the extent and clinical correlates of systemic inflammation remain incompletely defined. - Source: PubMed
Publication date: 2026/06/27
Francke Lotta SandelinAl-Bayatti AnsamZhang HanqianAlimohammadi MohammadTörmä HansSonkoly Enikö - To evaluate the impact of long-term carbamazepine monotherapy on bone metabolism and bone mineral density in women with epilepsy. - Source: PubMed
Rakhimbaeva G SMuratov F HYusupova D Y - : Obesity-related insulin resistance is accompanied by chronic low-grade inflammation, but the extent to which weight loss modifies circulating cytokines in a sex-specific manner remains insufficiently understood. The aim of this study was to assess sex-specific cytokine responses and metabolic adaptation in adults with obesity and insulin resistance following a six-month weight-reduction program (WRP). : Thirty-six participants (24 women and 12 men) with a value of Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) ≥ 2 underwent an individualized low-calorie diet combined with moderate physical activity and health education. Anthropometric, body composition, biochemical, oxidative stress, and cytokine parameters were evaluated before and after the intervention. : Both women and men showed significant reductions in body mass, Body Mass Index (BMI), waist circumference, visceral fat area (VFA), body fat mass (BFM), fasting glucose, HOMA-IR, modified Atherogenic Index of Plasma (new-AIP), malondialdehyde (MDA), and Oxidative Stress Index (OSI). Women additionally showed significant decreases in fat-free mass (FFM), skeletal-muscle mass (SMM), total body water (TBW), glycated hemoglobin A (HbA1c), and triacylglycerols, whereas cholesterol in high-density lipoproteins (HDL-C) increased significantly in men. Cytokine changes were selective rather than uniform. Interleukin-1 receptor antagonist (IL-1ra), Interleukin 6 (IL-6), and Tumor Necrosis Factor alpha (TNF-α) decreased in both women and men. In sex-stratified analyses, IL-1β decreased significantly only in women, whereas IL-7 decreased significantly only in men. ClinicalTrials.gov Registration: [NCT07645105] (retrospectively registered on [11 June 2026]). : A 6-month lifestyle-based weight-reduction program in adults with overweight or obesity and insulin resistance was associated with metabolic improvement, reduced oxidative stress, and partial attenuation of obesity-related low-grade inflammation. The observed cytokine and metabolic changes suggest sex-related patterns of immunometabolic adaptation to weight reduction. However, these findings should be interpreted cautiously because of the relatively small sex-stratified subgroups and the number of cytokine endpoints analyzed, and they require confirmation in larger, sex-balanced studies. - Source: PubMed
Publication date: 2026/06/18
Dydoń MariaBirková AnnaDolibog PawełČižmárová BeátaHubková BeátaCzuba ZenonZalejska-Fiolka PaulinaDydoń AgataKasperczyk SławomirSkrzep-Poloczek BronisławaZalejska-Fiolka Jolanta - Acute hepatitis B virus (HBV) infection encompasses a broad clinical spectrum, from self-limited hepatitis to acute liver injury (ALI), acute liver failure (ALF), subacute liver failure, and ALF on chronic HBV reactivation. This study investigates how host and viral factors interact to shape the clinical spectrum of HBV-associated ALF. - Source: PubMed
Publication date: 2026/06/25
Farci PatriziaBattista Davide DeEngle Ronald EChu EricChen ZhaochunJeffrey BrendanRule JodyNguyen HanhRaini SandraTakeda SoichiFollman DeanAlter Harvey JLee William M - Chimeric antigen receptor (CAR) T cell therapy has demonstrated remarkable clinical efficacy, but challenges remain in the therapeutic application for solid tumors, primarily due to poor infiltration capacity, suboptimal activity, and tumor antigen escape. Here, we found that the chemokine CCL3 plays a significant role in modulating intratumoral T cell cytotoxicity. However, CCL3 alone is insufficient to sustain durable CAR-T cell-mediated tumor killing, largely due to tumor-induced T cell death. In contrast, the combination of CCL3 with interleukin-7 (IL-7), a cytokine known to enhance T cell survival, exerted a potent synergistic effect. This combination significantly improved CAR-T cell infiltration and longevity in solid tumors, leading to robust anti-tumor efficacy without significant side effects or systemic toxicity. Mechanistically, CCL3 plus IL-7 promoted RUNX3 expression and facilitated the differentiation of CD69CD103 tissue-resident memory T (Trm) cells. Furthermore, treatment with CAR-T cells co-expressing CCL3 and IL-7 (3P7-CAR-T) remodeled the immune landscape of solid tumors, marked by an increased infiltration of M1-like macrophages and CD103 migratory dendritic cells. These changes enhance antigen presentation, thereby promoting the priming of endogenous anti-tumor T cell responses. Taken together, our results demonstrate that CCL3 synergizes with IL-7 to augment CAR-T cell memory and therapeutic effectiveness in solid tumors. - Source: PubMed
Publication date: 2026/06/22
Chen HuanpengLuo XiaoyunGao HuixinKe YujingZhan YuXu XiaotingXiong XiaoxiaoWei FengjiaoYang SiLiu ZhonghuaYu BolanHuang ZhaofengBian Yingjie